CONCLUSIONS MI and BRH are associated with comparable and durable mortality risks over one year in ACS patients undergoing PCI.
METHODS The COMMIT-HF is an ongoing single-center systolic HF registry (inclusion criteria: HF with LVEF <35%, exclusion: ACS). A total of 1798 patients were enrolled since 2009. Among them we have selected a group of patients with multivessel CAD qualified for PCI. The subjects were divided into complete (n¼188) and incomplete revascularization (n¼159) groups. Completeness of revascularization was defined as successful PCI of every angiographically significant lesion in all arteries with a diameter of 2mm without a patent surgical graft. All of the analyzed patients are followed up for a period of at least 12 months with all-cause mortality defined as primary endpoint.
RESULTS Patient characteristics are presented in table 1. Both groups showed no significant differences in clinical status and echocardiographic parameters, however there was a higher comorbidity rate in the incomplete revascularization group. Drug-eluting stents were implanted more frequently in the complete revascularization group (65,9% vs. 52,8%, p¼0,01) , with no other significant differences in PCI strategy with very low and comparable complication rates. All-cause mortality was significantly higher in the incomplete revascularization group both after 12-month (6,4% vs 20,1%, p<0,001) and 24-month (14,2% vs 27,2%, p¼0,004) follow-up period. In multivariate analysis complete revascularization was an independent factor improving survival (OR 0,33, 95% CI 0,14-0,74, p¼0,007). of treatment outcomes that may limit the generalizability and quality of the study findings. The aim of this study was to determine whether there existed significant heterogeneity of treatment by center, country, or baseline risk factors for 5-year MACCE rates in the SYNTAX trial.
METHODS Patient level-data from the 5-year results of the SYNTAX study were analyzed for the presence of geographical heterogeneity (site/country) in the effect of treatment (CABG vs PCI) on 5-yr MACCE rates. Fixed and random effects models examined potential interactions, followed by generalized linear mixed models testing effects of clinical co-variates, such as diabetes, smoking rates, lesion characteristics and procedural variations CONCLUSIONS As expected for this RCT, site-site and regional differences exist. Nonetheless, geographic variability in standard risk, responsiveness to treatment, and vulnerability to adverse outcomes, assessed by current models for heterogeneity analysis in clinical trials, shows no significant treatment effect. These findings highlight the utility and generalizability of the 5-year outcomes of the SYNTAX study.
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Incidence of Peri-Procedural Myocardial Infarction after Bifurcation Percutaneous Coronary Intervention According to Different Definitions: Insight from the Tryton IDE randomized trial BACKGROUND The incidence of peri-procedural myocardial infarction (PPMI) in patients treated with percutaneous coronary intervention (PCI) varies largely between studies, and its clinical relevance still remains a matter of debate. We sought to examine the incidence of PPMI after bifurcation PCI using different definitions from the TRYTON randomized trial.
METHODS The TRYTON trial randomized 704 patients with bifurcation undergoing PCI to the Tryton side branch (SB) stent with main branch (MB) DES vs. provisional SB treatment with MB DES. In the current study, we reported and compared the incidence of PPMI after PCI, defined according three different definitions: per protocol (CK-MB 3Â ULN), 3rd universal (troponin rise of > 5 Â ULN), and SCAI (CK-MB rise of !10 Â ULN).
RESULTS PPMI occurred in 81 out of 704 patients (11.5%) according to the protocol definition, in 137 patients (19.5%), according to the troponin-based third universal definition, and in 1.0% according to the SCAI definition, with no significant difference between the Tryton and provisional group (Table) . Access site (femoral vs radial; OR 0.60, 95% CI 0.37-0.98), main vessel lesion length (OR 1.04, 95% CI 1.00-1.07), and main vessel diameter stenosis (OR 1.02, 95% CI 1.00-1.05), the use of devices other than angioplasty balloon (OR 3.77, 95% CI 1.02-13.86), and the use of "non-study" stents were identified as independent predictors of per-protocol PPMI. At 12-month follow-up, there were no cardiac death in PPMI and two (5.9%) in no-PPMI patients (p¼0.61).
Patients who experienced protocol-defined PPMI had significantly more target vessel revascularizations (11.1% vs. 5.1%; p¼0.02) . BACKGROUND Previous studies have shown that deferral of revascularization in lesions with a fractional flow reserve (FFR) > 0.80 is safe and associated with significantly lower incidence of major adverse cardiovascular events (MACE) as compared to angiographically guided revascularization. DM patients have an accelerated atherosclerosis progression compared to patients without DM. Whether FFR-guided revascularization is also valid in DM patients is unknown, therefore we performed a retrospective study in our center.
METHODS We assessed all consecutive DM patients that underwent FFRguided revascularization between January 2011 and December 2013, and followed them until May 2015. We further divided these patients into two groups according to the presence or absence of !1 FFR-negative lesion (! 0.80) remaining after index revascularization. DM was defined as self-reported by treatment with anti-diabetic medication or diet. The primary endpoint was the incidence of MACE defined as a composite of death, myocardial infarction (MI), target lesion revascularization (TLR) or rehospitalization for acute coronary syndrome (ACS). Target lesion was defined as the lesion(s) in which the FFR was performed. Logistic regression analysis was performed to assess for predictors of MACE.
RESULTS
Of the 224 DM patients that underwent FFR-guided revascularization, 152(67.9%) had !1 FFR-negative lesion (Defer Group, DG) while 72(32.1%) had only FFR-positive lesions, with resultant index revascularization (Revascularization Group, RG). Overall, baseline characteristics were well matched between groups, however there were more females (37.5% vs 23.6%, p¼0.04) in the DG, while rates of smoking (19.7% vs 34.7%, p¼0.02) and prior PCI (41.4% vs 56.9%, p¼0.03) were higher in the RG. The MACE rate was 34.2% in the DG and 26.4% in the RG, p¼ 0.24. The incidence of death was similar in both groups 15.8% vs 15.3% p¼0.92. However a significantly higher rate of TLR (13.2% vs 4.2%, p¼0.038) and rehospitalization for ACS (33.6% vs 19.4%, p¼0.03) was observed in the DG group. Similarly a numerically higher incidence of MI was also observed but did not reach significance (7.2% vs 4.2%, p¼0.56). Logistic regression analysis showed that increasing age, elevated HbA1c and renal insufficiency
